XORTX Therapeutics (XRTX) announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days. These notifications do not impact the Company’s listing on the Nasdaq Capital Market at this time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRTX:
- XORTX Therapeutics Releases Annual Information Form for 2024
- XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses
- XORTX Advances Gout Treatment Program with FDA Discussions
- Xortx Therapeutics to provide Type B meeting package to FDA during next week
- XORTX Advances Gout Treatment Program with FDA Meeting Request